StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -$561.10M. The highest annual figure on record is $14.73B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$561.10M–
FY2024Dec 31, 2024-$152.85M–
FY2023Dec 31, 2023-$17.52M–
FY2022Dec 31, 2022-$1.11B-107.6%
FY2021Dec 31, 2021$14.73B+2972.7%
FY2020Dec 31, 2020$479.31M+1585.0%
FY2019Dec 31, 2019$28.45M+1120.9%
FY2018Dec 31, 2018$2.33M-95.1%
FY2017Dec 31, 2017$47.84M–
FY2016Dec 31, 2016-$26.56M–
FY2015Dec 31, 2015-$1.09M–
FY2014Dec 31, 2014-$21.04M-4849.4%
FY2013Dec 31, 2013$443.00K–
FY2012Dec 31, 2012-$32.41M–
FY2011Dec 31, 2011-$1.52M–
FY2010Dec 31, 2010-$39.10M-188.7%
FY2009Dec 31, 2009$44.09M–

More Sinovac Biotech figures

See a number that looks wrong?